Faculty profile

Humphrey Fonge

ResearcherUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Humphrey Fonge

Researcher

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
12 publications in the last five years, latest in 2026.
Senior (last) author on 10 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Actinium-225 Non-Small Cell Lung Cancer (Nsclc)Precision Medicine Terbium-161 Theranostics Chemistry Manufacturing Control (Cmc)Clinical Trial Enabling Study Good Manufacturing Practice

Latest papers

Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · senior author
Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.
International journal of pharmaceutics · 2026 · senior author
Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.
British journal of cancer · 2026 · senior author

All 12 publications

Latest funding

Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC
CIHR · 2025 · Nominated PI
$1,162,800
161Tb/225Ac-labeled anti-Nectin-4 radioimmunoconjugates with/without immune checkpoint inhibitors against NSCLC
CIHR · 2024 · Nominated PI
$1,017,450
Canada Research Chair - Tier 1
CIHR · 2024 · Nominated PI
$1,400,000

All 3 grants and awards

12 publications.

Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models.

Babeker H, Nwangele E, Monzer A, Pougoue Ketchemen J, Bato KE, Njotu FN, Tikum AF, Mercado T, Doroudi A, Torlakovic E, Gordon JR, Uppalapati M, Fonge H

Clinical cancer research : an official journal of the American Association for Cancer Research2026Senior author

DOI: 10.1158/1078-0432.ccr-26-0326 PMID: 42612016

Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.

Njotu FN, Garcia MD, Nwangele E, Babeker H, Pougoue Ketchemen J, Doroudi A, Price EW, Gordon JR, Uppalapati M, Fonge H

International journal of pharmaceutics2026Senior author

DOI: 10.1016/j.ijpharm.2026.126923 PMID: 42055153

Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.

Pougoue Ketchemen J, Monzer A, Njotu FN, Babeker H, Tikum AF, Nwangele E, Henning N, Hassani N, Ngong AF, Doroudi A, Fonge H

British journal of cancer2026Senior author

DOI: 10.1038/s41416-026-03393-2 PMID: 41946831

Development of angiostatin based radiopharmaceutical as a sensitive tool for detection of ATP synthase during acute vascular damage.

Das A, Florence T, Rodrigues CR, Ambros B, Singh J, Fonge H, Aulakh GK

Nuclear medicine and biology2026

DOI: 10.1016/j.nucmedbio.2026.109633 PMID: 42114414

[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.

Tikum AF, Fon DA, Njotu FN, Henning N, Nwangele E, Babeker H, Ketchemen JP, Doroudi A, Uppalapati M, Fonge H

Breast cancer research : BCR2026Senior author

DOI: 10.1186/s13058-026-02220-z PMID: 41546059

Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.

Pougoue Ketchemen J, Ahenkorah S, Nwangele E, Malaza SSP, Ooms M, Cardinaels T, Leekens S, Cleeren F, Fonge H

EJNMMI radiopharmacy and chemistry2025Senior author

DOI: 10.1186/s41181-025-00408-w PMID: 41428153

Maximizing therapeutic potential and safety: Exploring multi/dual-payload antibody conjugates as cancer theranostics.

Khosravifarsani M, Njotu FN, Fon DA, Fonge H

Advanced drug delivery reviews2025Senior author

DOI: 10.1016/j.addr.2025.115608 PMID: 40393542

An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.

Tikum AF, Henning NW, Pougoue Ketchemen J, Doroudi A, Babeker H, Njotu FN, Nwangele E, Monzer A, Gray B, Torlakovic E, Uppalapati M, Fonge H

Cancer research2025Senior author

DOI: 10.1158/0008-5472.can-24-2266 PMID: 40126545

Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering.

Bednova O, Pougoue Ketchemen J, Mslati H, Barok M, Joensuu H, Zeytuni N, Gentile F, Sanche L, Fonge H, Leyton JV

Biomolecules2025

DOI: 10.3390/biom15050606 PMID: 40427499

225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.

Babeker H, Njotu FN, Pougoue Ketchemen J, Monzer A, Tikum AF, Doroudi A, Nwangele E, Uppalapati M, Fonge H

Journal of nuclear medicine : official publication, Society of Nuclear Medicine2025Senior author

DOI: 10.2967/jnumed.124.268387 PMID: 39978811

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Actinium-225 Dear Professor Fonge, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Humphrey Fonge

Research

Latest papers

Latest funding

Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models.

Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.

Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.

Development of angiostatin based radiopharmaceutical as a sensitive tool for detection of ATP synthase during acute vascular damage.

[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.

Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.

Maximizing therapeutic potential and safety: Exploring multi/dual-payload antibody conjugates as cancer theranostics.

An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.

Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering.

225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.

Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC

161Tb/225Ac-labeled anti-Nectin-4 radioimmunoconjugates with/without immune checkpoint inhibitors against NSCLC

Canada Research Chair - Tier 1

Frequent collaborators

Humphrey Fonge

Maruti Uppalapati

Maruti Uppalapati

Léon Sanche

Natalie Zeytuni